Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EX1000 vs Biphasic Human Insulin in Type 2 Diabetes
NCT00698802Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jun 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of EX1000 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoint: Glycated Hemoglobin A1c at 8 weeks. Started Jun 2008; status: completed.
02
Drugs
EX1000
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00698802.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00698802.